Preventing and De-escalating Aggressive Behavior Among Adult Psychiatric Patients: A Systematic Review of the Evidence

Bradley N. Gaynes, M.D., M.P.H., Carrie L. Brown, M.D., M.P.H., Linda J. Lux, M.P.A., Kimberly A. Brownley, Ph.D., M.A., Richard A. Van Dorn, Ph.D., M.S.W., Mark J. Edlund, M.D., Ph.D., Emmanuel Coker-Schwimmer, M.P.H., Rachel Palmieri Weber, Ph.D., Brian Sheitman, M.D., Theodore Zarzar, M.D., Meera Viswanathan, Ph.D., Kathleen N. Lohr, Ph.D., M.A.

Objective: The project goal was to compare the effectiveness of strategies to prevent and de-escalate aggressive behaviors among psychiatric patients in acute care settings, including interventions for reducing use of seclusion and restraint.

Methods: Relevant databases were systematically reviewed for comparative studies of violence prevention and deescalation strategies involving adult psychiatric patients in acute care settings. Studies (trials and cohort studies) were required to report on aggression or seclusion or restraint outcomes. Both risk of bias, an indicator of quality of individual studies, and strength of evidence (SOE) for each outcome were independently assessed by two study personnel.

Results: Seventeen primary studies met inclusion criteria. Evidence was limited for benefits and harms; information about characteristics that might modify the interventions' effectiveness, such as race or ethnicity, was especially

Aggressive behavior connotes using actual physical violence toward oneself, others, or property or making specific imminent verbal threats (1). In health care settings, approaches for de-escalating actively aggressive behavior have historically involved using either seclusion (involuntary placement of a patient in a locked room or area from which the patient is not allowed to leave) or restraint (involuntary administration of mechanical, pharmacologic, or physical interventions) (2,3). However, practice standards have moved toward less restrictive and more patient-centered approaches. Since the late 1990s, the Centers for Medicare and Medicaid Services (3) and the Joint Commission (4) have required that seclusion and restraint be used only for a behavior that "jeopardizes the immediate physical safety of the patient, a staff member, or others" (5) (including other patients) and only when less restrictive measures have failed.

Despite practice guidelines and quality-of-care measures that support reducing use of seclusion and restraint

Psychiatric Services 68:8, August 2017

limited. All but one study had a medium or high risk of bias and thus presented worrisome limitations. For prevention, risk assessment reduced both aggression and use of seclusion and restraint (low SOE), and multimodal interventions reduced the use of seclusion and restraint (low SOE). SOE for all other interventions, whether aimed at preventing or de-escalating aggression, and for modifying characteristics was insufficient.

Conclusions: Available evidence about strategies for preventing and de-escalating aggressive behavior among psychiatric patients is very limited. Two preventive strategies, risk assessment and multimodal interventions consistent with the Six Core Strategies principles, may effectively lower aggressive behavior and use of seclusion and restraint, but more research is needed on how best to prevent and de-escalate aggressive behavior in acute care settings.

Psychiatric Services 2017; 68:819-831; doi: 10.1176/appi.ps.201600314

(6,7), data in the United States and Europe show that 10% to 30% of patients (adolescents, adults, and elderly persons) admitted to acute psychiatric units receive these procedures (8–10). Thus much interest now focuses on using alternatives to seclusion and restraint. These strategies can address preventing aggressive behavior, reducing aggressive behavior once it has already developed, or both. Most alternatives are strongly influenced by the National Association of State Mental Health Program Directors' Six Core Strategies to prevent aggressive behavior, which include leadership toward organizational change, use of data to inform practice, workforce development, use of seclusion and restraint prevention tools, consumer roles in inpatient settings, and debriefing techniques (11).

Preventive strategies can be either multicomponent interventions that apply to all individuals (whether or not they are aggressive) or specific procedures aimed at persons who are at especially high risk of becoming aggressive. General preventive strategies emphasize providing a calm environment in which aggression is less likely to develop; they usually focus on entire care units. They can include risk assessment (12); milieu-based changes, such as the use of sensory rooms (13); staffing changes, such as increased staffto-patient ratios (14); specific staff training programs (15); and peer-based interventions (16).

Specific preventive strategies often try to intercede before the development of agitation, which is seen as a risk factor for becoming aggressive. These techniques can involve use of supportive (often referred to as nonconfrontational) language and other verbal de-escalation techniques, cognitive-behavioral techniques, pharmacologic intervention for treating the underlying psychiatric illness, and recognition of triggers for aggressive behavior. These preventive approaches can overlap; specific strategies may also be applied on a unitwide basis.

If patients become actively aggressive, clinicians can use seclusion with or without restraint, restraint by itself, or alternative strategies. In such cases, alternatives can include the use of emergency response teams (17,18). In addition, clinicians can employ pharmacologic interventions to reduce agitation quickly (rather than more gradually by treating the underlying illness).

The Evidence-Based Practice Center (EPC), under a contract with the Agency for Healthcare Research and Quality (AHRQ), conducted a systematic review of the effectiveness of strategies for preventing aggressive behavior, comparing the effectiveness of alternative strategies with each other or with the use of seclusion and restraint. As authors of the study, we conceptualized "de-escalate" in terms of both preventing aggressive behaviors and reducing use of seclusion and restraint. The focus of the review was on studies involving psychiatric patients who were hospitalized in acute health care settings with lengths of stay of fewer than 35 days. For this article, we included all acute care settings regardless of length of stay to make our findings applicable to settings that may have a longer length of study, such as state hospitals.

This article addressed four main issues for adult psychiatric patients in acute care settings. First, for those without aggressive behavior, what are the comparative benefits and harms of strategies to prevent aggressive behavior? Second, for those with active aggression, what are the comparative benefits and harms of strategies to de-escalate aggressive behavior? Third, for those with active aggression, what are the comparative benefits and harms of strategies to reduce the use of seclusion and restraint? Fourth, what characteristics, such as race and ethnicity, modify either benefits or harms of the strategies above to prevent or de-escalate aggressive behavior?

METHODS

We searched MEDLINE (via PubMed), Embase, the Cochrane Library, Academic Search Premier, PsycINFO, and CINAHL (Cumulative Index to Nursing and Allied Health Literature) for studies from January 1, 1991, to February 3, 2016 (19). We also manually searched reference lists of pertinent reviews, trials included in those reviews, and background articles to identify relevant citations that our searches might have missed. To find relevant gray literature, we followed guidance from the AHRQ's "Methods Guide for Effectiveness and Comparative Effectiveness Reviews" (20).

Our searches focused on comparative studies of de-escalation strategies (seclusion, restraint, or alternatives to seclusion or restraint) for adult patients with psychiatric disorders or severe psychiatric symptomatology who are at risk of, or present with, aggressive behavior across various acute care settings. Studies that limited populations to patients with dementia were ineligible. Studies that did not differentiate between results for patients with aggression and for those who were not currently aggressive were included in the prevention analyses.

For studies to be included, we required that interventions target reducing aggressive behavior or decreasing use of seclusion and restraint (or both). Eligible studies were required to have reported on at least one of our two primary outcomes: decreased aggression in terms of frequency, severity, or duration (measured by either direct counts or validated aggression scales) and reduced use of seclusion or restraint (decreased rate, amount, or duration). Investigators must have tested interventions in acute care settings (general hospitals, psychiatric hospitals, and emergency departments in these hospitals) with no limitations by length of stay. Studies were required to have had a control group, potentially allowing for causal inferences to be made. Randomized controlled trials (RCTs), cluster randomized controlled trials (CRTs), nonrandomized controlled trials (NRCTs), and cohort studies were eligible, but pre-post designs were not. [The full eligibility criteria are available as an online supplement to this article.]

Two research team members independently reviewed all titles and abstracts against our inclusion and exclusion criteria. For potentially eligible abstracts, two investigators independently reviewed the full text to determine final inclusion or exclusion. To assess the risk of bias of included studies, we followed EPC methods guidance (21) and each investigator individually rated the risk of bias for each relevant outcome as low, medium, or high. Specifically, we used the Cochrane Risk of Bias tool to appraise RCTs and CRTs (where the cluster, or group, that was randomized was the unit in the facilities where the studies took place). To appraise the risk of bias in NRCTs and cohort studies, we employed criteria from the Research Triangle Institute Risk of Bias Tool for Observational Studies (22). To minimize risk of bias for addressing adverse outcomes, or harms-a key focus of the study-we required a minimum total sample of 100 patients for NRCTs and cohort studies, consistent with our work in prior reviews (23).

Two investigators independently graded the strength of evidence (SOE) for primary outcomes on the basis of guidance established by the EPC (24) for incorporating five key domains: study limitations (study design and aggregate risk of bias), consistency, directness (whether evidence links an intervention directly to a relevant health outcome), precision (including whether a study included the number of patients required for an adequately powered individual trial [optimal information size, or OIS]) (25), and reporting bias.

RESULTS

Evidence Base

Searches of all sources identified a total of 1,983 potentially relevant citations [see online supplement]. Twenty-two studies that otherwise met selection criteria were deemed ineligible because of a pre-post design. We identified 17 eligible controlled studies (described in 22 articles) that provided data for this review; the studies included more than 3,628 participants, and the samples ranged in size from 20 to 973 participants (not all studies reported sample size) (26-47). Thirteen studies were randomized trials (eight RCTs and five CRTs), two were NRCTs, and two were retrospective cohort studies (Table 1). Nearly half took place in the United States; most interventions took place in public psychiatric hospitals or inpatient psychiatric treatment units or facilities. For studies reporting demographic characteristics for their patient populations, the mean age ranged primarily between 38 and 40 years, the distribution of men and women varied widely across studies, and race or ethnicity was sparsely reported.

There are no agreed-upon categories for stratifying violence prevention and de-escalation interventions, so we sorted the interventions described in the eligible studies into the following five broad categories on the basis of the intervention's main focus: staff training, risk assessment, multimodal programs, environmental or group psychotherapeutic interventions, and medication protocols. Table 2 describes the design of the eligible studies in each of the intervention categories.

Staff training interventions for clinical staff who provide acute care to patients with psychiatric symptomatology aim to equip staff with new skills or to promote staff attitudes that can help prevent or de-escalate aggression. Risk assessment interventions involve clinical staff's use of structured assessment of individual patients' risk of becoming actively aggressive. Multimodal programs involve a combination of various intervention types, such as enhanced administrative review of patients with high restraint use and staff training in strategies to better manage patients' difficult behavior; the goal of the programs is to decrease the occurrence of active aggression or use of seclusion or restraint for managing active aggression.

Environmental or group psychotherapeutic interventions involve changes to the physical environment of the acute care setting or the introduction of group psychotherapeutic interventions meant to diminish precursors of active aggression. Finally, medication protocols encompass any medicationfocused intervention to de-escalate active aggression, ranging from hospital- or unitwide policies specifically affecting how or which medications can be used to manage active aggression to the use of one or more emergency medications. Key characteristics of the eligible studies are listed in Table 3 [see the online supplement for more details about the studies and their risk of bias assessments].

TABLE 1. Characteristics of 17 studies included in this literature review

| Characteristic | Ν | % |
|--|----|----|
| Design | | |
| Randomized controlled trial | 8 | 47 |
| Cluster randomized trial | 5 | 29 |
| Nonrandomized controlled trial | 2 | 12 |
| Retrospective cohort study | 2 | 12 |
| Comparison arm | | |
| Active treatment | 9 | 53 |
| Usual care | 8 | 47 |
| Country | | |
| United States | 8 | 47 |
| Other | 9 | 53 |
| Funding | | |
| Government | 5 | 29 |
| Foundation or nonprofit | 1 | 6 |
| Pharmaceutical company | 1 | 6 |
| Multiple sources (pharmaceutical and government) | 1 | 6 |
| Multiple sources (foundation or | 1 | 6 |
| nonprofit, treating hospital, and | | |
| government) | 4 | 6 |
| No financial support | 1 | 6 |
| Not reported | / | 41 |
| Setting | c | 75 |
| Public psychiatric hospital | 6 | 35 |
| Inpatient psychiatric treatment unit or facility ^a | 5 | 29 |
| Multiple settings (inpatient psychiatric or forensic hospitals) | 1 | 6 |
| General medical hospital | 1 | 6 |
| General emergency department | 2 | 12 |
| Psychiatric emergency department | 2 | 12 |
| Primary outcome ^b | | |
| Aggression | 13 | 77 |
| Seclusion | 5 | 29 |
| Restraint | 4 | 24 |
| Seclusion and restraint | 5 | 29 |
| Harm | 9 | 53 |
| Risk of bias | | |
| Low | 1 | 6 |
| Medium | 9 | 53 |
| High | 7 | 41 |

^a Further information about the studies' public, private, or academic status was not available.

^b The number of studies listed exceeds 17 because multiple studies measured more than one primary outcome.

Overall SOE for Findings

The highest SOE grade for any outcome was low. The outcomes with low SOE involved two types of preventive interventions; two studies compared the benefits of risk assessment and one study compared the benefits of a multimodal intervention with usual care (Table 4). The SOE was insufficient for all other preventive interventions, for de-escalating interventions, and for modifying characteristics. For all ratings, the supporting evidence had medium risk of bias, had unknown consistency (because each finding was supported by a single study), was direct, and had precision. Of note, the CRTs in this

| | T () | | | De-escalation and reduction in seclusion | Modifying |
|---|-------------------------|----------------------|--|--|-----------|
| Intervention | Type of study | Prevention | De-escalation | or restraint | variables |
| Staff training Kontio et al., 2014 (29) Smoot and Gonzales, 1995 (46) | CRT CRT | Benefits and harms | | Benefits | |
| Risk assessment Abderhalden et al., 2008 (27) Van de Sande, et al., 2011 (34) | CRT CRT | Benefits Benefits | | | |
| Multimodal program Putkonen et al., 2013 (32) | CRT | Benefits | | | |
| Environmental or group psychotherapeutic intervention Carlson and Holm, 1993 (43) | Retrospective cohort | | | Benefits | |
| Nurenberg et al., 2015 (44) | RCT | Benefits | | | |
| Medication protocol | | | | | |
| Isbister et al., 2010 (26) Dorevitch et al., 1999 (28) | RCT RCT | | Benefits and harms Benefits and harms | | |
| Michaud et al., 2014 (31) | Retrospective cohort | | | Benefits | |
| Georgieva et al., 2013 (33) | RCT | | | Benefits | |
| Volavka et al., 2004 (35) | RCT | | Benefits and harms | | |
| Bieniek et al., 1998 (38) | RCT | | Benefits and harms | | |
| Krakowski et al., 2006 (39) | RCT | | Benefits and harms | | Harms |
| Villari et al., 2008 (42) | NRCT | | Benefits and harms | | |
| Richards et al., 1998 (45) Wilhelm et al., 2008 (47) | RCT NRCT | | Benefits and harms Benefits and harms | | |

TABLE 2. Available evidence from 17 studies of interventions for preventing or de-escalating aggressive behavior, decreasing use of seclusion and restraint, and identifying variables that modify use of interventions, by type of intervention^a

^a Abbreviations: CRT, cluster randomized trial; NRCT, nonrandomized controlled trial; RCT, randomized controlled trial

review did not control for clustering in their statistical analyses, which weakened the SOE grade for those interventions.

Preventing Aggressive Behavior

Benefits. Two CRTs of risk assessment protocols provided evidence supporting benefits of this preventive approach compared with usual care; such protocols decreased subsequent aggressive incidents (27,34) (Table 4). One CRT reported a lower risk of severe aggressive incidents and a lower number of physical attacks (27); the other reported a decrease in the risk of any aggressive incident (34). Both outcomes had low SOE.

These studies also yielded evidence that risk assessment reduced subsequent use of seclusion and restraint. Compared with usual care units, units administering risk assessment reported use of significantly fewer coercive measures (involving a range of measures from forced injection of psychotropic medication to seclusion and restraint) (27) and reported that patients spent significantly fewer hours in seclusion (34). Both outcomes had low SOE.

A multimodal intervention based on the Six Core Strategies also had evidence supporting effectiveness in reducing subsequent use of seclusion and restraint (Table 4). In one CRT, units employing such interventions reported greater reductions compared with usual care units in the percentage of patient-days involving seclusion, restraint, or room observation and shorter duration of seclusion and restraint use (32). Both outcomes had low SOE.

Two studies provided insufficient evidence of benefit for other interventions. One CRT of staff training in interpersonal communication found fewer incidents of seclusion and restraint and a larger decrease in incidents of seclusion and restraint compared with usual care on a control unit (46). One RCT of an environmental or group psychotherapeutic intervention (equineassisted therapy) provided insufficient evidence of pre-post reductions in the rate of violent incidents and mean monthly episodes of seclusion or restraint (44). No studies assessed medication protocols in patients without active aggression.

Harms. One CRT addressed harms of staff training to prevent aggressive behavior, but the outcomes had insufficient SOE (46). No eligible studies examined harms of any of the other strategies to prevent aggressive behavior.

De-Escalating Aggressive Behavior

Benefits. Eight studies (five RCTs [26,28,33,38,45], two NRCTs [42,47], and one retrospective cohort study [31]) assessed various medication protocols for de-escalating aggressive behavior but provided insufficient evidence to assess their benefits. Two trials (each reported in two separate articles) both conducted on inpatient psychiatric units, had significant findings but small sample sizes that did not meet

the minimum criteria for OIS (35,36,39,40). Most of the remaining studies of medication protocols found no differences between active interventions, but they had been underpowered to test noninferiority.

No relevant studies of the effects of staff training, risk assessment, multimodal, or environmental or group psychotherapeutic interventions on de-escalating aggressive behavior were identified.

Harms. Six RCTs (26,28,35,38,42,45) and two NRCTs (42,47) provided harms data for medication protocols, but the outcomes had insufficient SOE. Two RCTs found significantly higher weight gain among patients treated with olanzapine or clozapine compared with patients receiving haloperidol, but their combined sample size did not reach the minimum OIS (37,41). Another RCT found greater extrapyramidal symptom severity (indexed by the percentage of patients prescribed benztropine) in the risperidone-treated group versus the clozapine or haloperidol groups (36), but similarly it did not meet the OIS threshold, and the outcomes had insufficient SOE. The other five studies reported small numbers of events and performed no statistical testing; SOE was insufficient for all outcomes.

No eligible studies tested harms of staff training, risk assessment, multimodal, or environmental protocols for de-escalating aggressive behavior.

Reducing Seclusion and Restraint Use

Benefits. Four studies measured the benefits of strategies to reduce use of seclusion and restraint among patients with active aggression, but there was insufficient SOE for all reported outcomes (29,31,33,43). No eligible studies tested the benefits of risk assessment or multimodal interventions for reducing seclusion and restraint.

Harms. No studies provided information on the comparative harms of any intervention for reducing seclusion and restraint use among patients with active aggression.

Modifying Comparative Benefits or Harms of Strategies

Information about variables that might modify the effectiveness of interventions was limited. One RCT found significantly greater increases in weight, triglycerides, and cholesterol levels among black patients treated with clozapine compared with white or Hispanic patients treated with haloperidol, but the sample size did not reach the minimum OIS (insufficient SOE) (41).

DISCUSSION

Key Findings

Our review aimed to fill gaps in available literature about the comparative effectiveness of various strategies to prevent aggressive behavior, de-escalate aggressive behaviors, or decrease reliance on seclusion or restraint in acute care settings. An overarching objective of these strategies, of course, is to improve health outcomes for patients who are actively aggressive or at risk of acute aggressive behavior.

Overall, the evidence base was extremely limited. We identified 17 studies (mainly RCTs and CRTs) for which we could grade the SOE of one or more outcomes. Most evidence addressed preventive, unitwide programs rather than interventions specifically targeting actively aggressive patients; this focus represented the core difference between the CRTs (which randomize groups) and the RCTs (which randomize individuals). Moreover, some of these analyses included patients who were not actively aggressive These factors prevented us from attributing reduction of aggressive behavior among actively aggressive patients to any particular intervention. Furthermore, inexact descriptions of many interventions made it difficult to attribute a change to particular components. For example, the multimodal intervention had components of risk assessment and staff training, and distinguishing between their components was challenging.

None of the comparative data from the studies supported an SOE grade of higher than low, and all findings with low SOE were from studies of preventive interventions. The two studies of risk assessment protocols identified fewer aggressive incidents (34) and lower rates of severe aggressive incidents and physical attacks (27) compared with the usual care conditions. The protocols overlapped somewhat but differed in important ways. Both trials used the Brøset Violence Checklist as part of the protocol, but the trial from the Netherlands used a more comprehensive protocol that included completing a crisis monitor form and the Kennedy Axis V (short version) on a daily basis and the full version of the Kennedy Axis V, the Brief Psychiatric Rating Scale, the Dangerousness Scale, and the Social Dysfunction and Aggression Scale on a weekly basis (34). The trials also differed in the length of time during which they evaluated their risk assessment protocols. For example, one study (27) implemented the risk assessment protocol for the first three days of the patient's hospital stay, whereas the other study (34) used the risk assessment protocol throughout each patient's hospital stay.

The CRT of a multimodal intervention examined the safety and effectiveness of seclusion or restraint reduction strategies (modeled after the Six Core Strategies [11]) in the setting of high-security psychiatric units of a Finnish state hospital (32). Unlike prior examination of the Six Core Strategies in the United States (48), this CRT included data from a control group; thus, it provided the first outcome data eligible for an SOE assessment. Specifically, it reported decreases in the proportion of patient-days in seclusion, restraint, or room observation and in the duration of seclusion or restraint use. Importantly, both reductions were achieved without a concomitant increase in violent incidents, and these results were demonstrated in a patient population inherently at high risk of aggression (males with schizo-phrenia and history of violent behavior).

Our work is consistent with prior findings. Earlier reviews emphasized the lack of high-quality intervention

| Intervention | Study design | Risk of bias | Clinical setting | Country | z | Duration of intervention | Intervention and comparison groups | Patient population |
|---|-------------------------|-----------------|---|-----------------|------------------|-----------------------------|--|--|
| Staff training Kontio et al., 2014 (29); Kontio | CRT | High | Psychiatric hospitals | Finland | ц | 2 years | Online eLearning course for unit nurses on managing aggression or violence and | Inpatients on acute, closed units that practice seclusion or |
| et al., z011 (50) Smoot and Gonzales, 1995 (46) | CRT | High | (8 units) Inpatient psychiatric recidivist units | United States | nr ^b | 6 months | preventing coercion; education as usual Empathic interpersonal communication training program for hospital staff; usual care | restraint Primary diagnosis of mental illness for patients who had returned to the hospital within 1 year of a previous discharge |
| Risk assessment Abderhalden et al., 2008 (27) | CRT | Medium | Psychiatric inpatient treatment facilities | Switzerland | 973 ^c | 3 months | Structured risk assessment by using BVC for every new patient twice a day during the first 3 days of hospitalization (N=390); usual | Inpatients, most with an acute psychiatric disorder |
| Van de Sande et al., 2011 (34) | СКТ | Medium | Acute psychiatric units | The Netherlands | 458 | 30 weeks | Structured risk assessment for 5 minutes daily by using BVC and short version of Kennedy Axis V and for 15 minutes weekly by using full version of Kennedy Axis V, BPRS, Dangerousness Scale, and SDAS (N=207); usual care or treatment as usual (N=251) | Patients admitted to acute psychiatric units, 74% with psychotic disorders and 25% with personality disorders |
| Multimodal intervention Putkonen et al., 2013 (32) | CRT | Medium | Public psychiatric hospital | Finland | nr ^d | 6 months | Implementation of Six Core Strategies for Reducing Seclusion and Restraint Use; usual care or treatment as usual | Male inpatients in high-security units who had psychotic illness and a history of violence |
| Environmental or group psychotherapeutic intervention | | | | | | | | |
| Carlson and Holm, 1993 (43) | Retrospective cohort | High | State psychiatric hospital | United States | 120 | 90 days | Occupational therapy at least 1 time every 30 days (N=60); no occupational therapy in at least 1 of the 3 30-dav periods (N=60) | Patients with at least a 90-day inpatient stay on psychiatric unit; only data from first 90 days of stav were included |
| Nurenberg et al., 2015 (44) | RCT | Medium | State psychiatric hospital | United States | 06 | 3 months | Equine-assisted by chotherapy (N=24); canine-assisted psychotherapy (N=25); environmentally enhanced social skills group psychotherapy (N=23); usual care (N=18) | Inpatients with "aggressive or regressed behavior" or "persistent social isolation" and difficulty engaging in discharge-related programs |
| Medication protocol Isbister et al., 2010 (26) | RCT | Medium | Public psychiatric hospital | Australia | 91 | 6 hours | Droperidol, 10 mg im (N=33); midazolam, 10 mg im (N=29); droperidol, 5 mg im, plus midazolam, 5 mg im (N=29) | Patients presenting to the emergency department with violence and acute behavioral disturbance and requiring both physical restraint and parenteral sedation continued |

TABLE 3. Key characteristics of 17 studies of interventions to de-escalate aggressive behaviors in acute care settings, by intervention type^a

| TABLE 3, continued | | | | | | | | |
|---|-------------------------|-----------------|--|-----------------|-----|--|---|--|
| Intervention | Study design | Risk of bias | Clinical setting | Country | z | Duration of intervention | Intervention and comparison groups | Patient population |
| Dorevitch et al., 1999 (28) | RCT | Medium | Psychiatric hospital | Israel | 28 | 90 minutes, during aggressive event | Haloperidol, 5 mg im (N=13); flunitrazepam, 1 mg im (N=15) | Acute-unit patients with active psychosis, disruptive or aggressive behavior, pronounced psychomotor aditation or violent outbursts |
| Michaud et al., 2014 (31) | Retrospective cohort | High | Public psychiatric hospital | United States | 200 | 24 hours | Delirium treatment within 24 hours (N=102); no delirium treatment within 24 hours or treatment after 24 hours (N=98) | Adults in an intensive concernent with a documented positive delirium screen at time of mechanical ventilation |
| Georgieva et al., 2013 (33) | RCT | High | Psychiatric hospital | The Netherlands | 520 | 144 weeks | Intervencion of first choice for agitation and risk of violence: involuntary medication (N=236); seclusion (N=284) | Patience admit to the source units, most with either addiction or a psychotic, mood, personality, or posttraumatic stress disorder |
| Volavka et al., 2004 (35): Volavka et al., 2002 (36); Czobor et al., 2002 (37) | RCT | Medium | State psychiatric hospitals | United States | 157 | 14 weeks | Clozapine, oral 500 mg/day (N=40); olanzapine, oral 20 mg/day (N=39); risperidone, oral 8 mg/day (N=41); haloperidol, oral 20 mg/day (N=37) | Treatment-resistant inpatients diagnosed with chronic schizophrenia or schizoaffective disorder |
| Bieniek et al., 1998 (38) | RCT | Low | Psychiatric emergency service (in hospital) | United States | 20 | 3 hours | Haloperidol, 5 mg im plus lorazepam 2 mg im (N=9); lorazepam, 2 mg im (N=11) | Patients with serious, acutely agitated or aggressive behavior who met clinical criteria for use of chemical restraint |
| Krakowski et al., 2006 (39) ; Krakowski et al., 2008 (40); Krakowski et al., 2009 (41) | RCT | Medium | State psychiatric in-hospital facilities | United States | 110 | 12 weeks | Clozapine, oral 500 mg/day (N=37); olanzapine, oral 20 mg/day (N=37); haloperidol, oral 20 mg/day (N=36) | Patients with confirmed episode of physical assault directed at another person during their current hospitalization and some persistence of addression |
| Villari et al., 2008 (42) | NRCT | Medium | Psychiatric in-hospital emergency service | Italy | 101 | 72 hours | Risperidone, oral 2–6 mg/day (N=27); olanzapine, oral 10–20 mg/day (N=24); quetiapine, oral 300–800 mg/day (N=22); haloperidol, oral 5–15 mg/day (N=28) | Inpatients with psychosis who require emergency medication for control of agitation |
| Richards et al., 1998 (45) | RCT | High | Large urban university emergency department | United States | 202 | 60 minutes | Droperidol, 2.5–5.0 mg iv (N=102); lorazepam, 2–4 mg iv (N=100) ^e | Acutely agitated patients with violent, controlled, or uncontrolled muscular movement placing themselves and staff at danger and requiring constant supervision |

continued

| continue |
|----------|
| m |
| ЗĽ |
| Ā |

| TABLE 3, continued | | | | | | | | |
|------------------------------|-----------------|-----------------|---|---------|-----|-----------------------------|--|---|
| Intervention | Study design | Risk of bias | Clinical setting | Country | z | Duration of intervention | Intervention and comparison groups | Patient population |
| Wilhelm et al., 2008 (47) | NRCT | High | Psychiatric or forensic hospitals | Germany | 558 | 6 days ^f | Olanzapine, oral dose (N=390); non- olanzapine medication, oral dose (N=168); risperidone, oral dose (N=72); non-risperidone medication, oral dose (N=486); haloperidol, oral dose (N=132); non-haloperidol medication, oral dose (N=426) ⁹ | Inpatients with psychiatric disorders who presented with agitation with or without aggression and required antipsychotic treatment and who were newly admitted to a psychiatric hospital (98%) or a foreneic hosoital (2%) |
| | | | | | | | | |

Abbreviations: BPRS, Brief Psychiatric Rating Scale; BVC, Brøset Violence Checklist; CRT, cluster randomized trial; nr, not reported; NRCT, nonrandomized controlled trial; RCT, randomized controlled trial; SDAS, Social Dysfunction and Aggression Scale

² An average of 92 patients were discharged per month in each unit, meaning about 184 patients were included in the study each month.

structured risk assessment without randomization units that preferred to introduce the study protocol of five patients admitted to the ^c Does not include

Each arm accounted for approximately 1,000 patient-days per month

basis of patients' weight, which was visually estimated by the treating clinician. Dosages of study drugs were selected on the

⁷ Patients' antipsychotic treatment was categorized as including any olanzapine or not, including any risperidone or not, and including any haloperidol or not. The three cohorts thus overlapped, because each Baseline was day 1, and the following 5 days (days 2–6) represented the follow-up period over the first 6 days of their hospitalizations. The study followed enrolled patients

cohort included all patients who received the respective drug in any amount and at any time throughout the 5-day study period

studies of strategies to prevent the development of aggressive behavior in acute care settings (49-52). An absence of relevant literature on interventions for actively aggressive behavior has been similarly reported, regardless of whether alternative strategies to seclusion and restraint were being compared with each other (49-51,53) or with seclusion and restraint (49,51). A lack of literature about comparative harms of these interventions has also been identified (54). Our review updates and confirms these findings. Of particular relevance for clinical and administrative audiences, the review expands considerations of potentially relevant interventions to include staff training, environmental or group psychotherapeutic, multimodal, and pharmacologic interventions not previously reported.

Our review adds to existing reviews by including findings highlighting the potential benefits of two preventive interventions. First, a general application of a strategy that involves a risk assessment component for all individuals on inpatient psychiatric units-not just actively aggressive patients-may produce less aggressive behavior and less use of seclusion and restraint compared with usual care. The former finding extends what is known about the relationship between risk assessment and subsequent behavior. Earlier reviews of risk assessment found that using such a service was associated with decreased agitation (12), often considered an intermediate precursor of more dangerous aggressive behavior. Lowering agitation may or may not lead to decreased aggression, but our review found that risk assessment may lead to reduced subsequent aggression (as indicated by fewer aggressive incidents).

Second, both risk assessment and multimodal interventions may lower use of seclusion and restraint (as indicated by duration of seclusion or restraint and by use of forced treatment, including seclusion and restraint). These findings highlight a key potential benefit relevant to practice guidelines and quality-of-care measures advocating decreasing use of seclusion and restraint. Nevertheless, the SOE for these findings (all from CRTs) was limited by data analyses that did not account appropriately for the clustering of these data; this drawback likely affected each trial's results, for example, by increasing the risk of a type I error. Further, the three studies forming the basis for the low SOE findings (risk assessment [27,34] and multimodal interventions [32]) were conducted outside the United States. How substantially clinical practice outside the United States differs from current U.S. practice is unclear, which may bring into question the applicability of findings from non-U.S. studies.

Potential Clinical and Policy Implications

The handful of findings that we graded as low SOE may provide some clinical or policy implications. In particular, a limited number of risk assessment interventions subsequently led to less aggressive behavior and reduced the use of seclusion and restraint. These findings suggest that clinicians must consider carefully the role of these strategies on psychiatric inpatient units. Specifically, acute care practitioners and

TABLE 4. Primary outcomes with low strength of evidence among studies of interventions for preventing aggressive behavior among adult psychiatric patients^a

| Outcome | Study | Intervention | Comparison group | Ν | Findings and direction of effect |
|--|-----------------------------------|-------------------------|---------------------|--|--|
| Change in aggressive behavior N of aggressive incidents | Van de Sande et al., 2011 (34) | Risk assessment | Usual care | N=170 (baseline), N=458 (intervention period) | Significant 68% relative risk (RR) reduction with risk assessment (p≤.001); failure to control for intraclass correlations weakened |
| Rate of severe aggressive incidents | Abderhalden et al., 2008 (27) | Risk assessment | Usual care | N=973 (postintervention) | the finding. Significantly lower risk with structured risk assessment (RR=.59; 95% confidence interval (CI)=.41–.83, p<.001); failure to control for intraclass correlations weakened the finding. Decrease since baseline of 41% with risk assessment vs. 15% with usual care; no statistical testing reported |
| N of physical attacks | Abderhalden et al., 2008 (27) | Risk assessment | Usual care | N=973 (postintervention) | Significantly greater decrease with risk assessment vs. usual care (41% vs. 7%, p<.001); failure to control for intraclass correlations weakened the finding. |
| Change in seclusion or restraint | | | | | |
| Hours in seclusion | Van de Sande et al., 2011 (34) | Risk assessment | Usual care | N=170 (baseline), N=458 (intervention period) | Significant 45% RR with risk assessment $(p \le .001)$; failure to control for intraclass correlations weakened the finding |
| N of coercive incidents ^b | Abderhalden et al., 2008 (27) | Risk assessment | Usual care | N=973 (postintervention) | Significant decrease of 27% from baseline with risk assessment compared with increase of 10% with usual care (p<.001); failure to control for intraclass correlations weakened the finding |
| Proportion of patient-days with seclusion, restraint, or room observation | Putkonen et al., 2013 (32) | Multimodal ^C | Usual care | Not reported, but each arm accounted for approximately 1,000 patients | Significant difference in calculated change with intervention vs. usual care (-15% vs6%, p=.001). No between-group CI reported. Failure to control for intraclass correlations weakened the finding. |
| Hours in seclusion or restraint | Putkonen et al., 2013 (32) | Multimodal ^C | Usual care | Not reported, but each arm accounted for approximately 1,000 patients | Significant difference in calculated change with intervention vs. usual care (decrease of 54 hours vs. increase of 17 hours, p=.001). No between-group CI reported. Failure to control for intraclass correlations weakened the finding. |

^a All of the studies were cluster randomized trials. Due to differential operationalization of the two risk assessment studies, it was not possible to conduct a direct comparison of the two studies.

^b Coercive measures covered a wide range of measures from forced injection of psychotropic medication to seclusion and mechanical restraint.

^c Based on the Six Core Strategies for Reducing Seclusion and Restraint Use (11)

administrative staff must balance the low SOE with the reality that violence is a pressing—indeed, growing—concern and poses significant disruptions to quality of care in such settings. Broad implementation of a well-validated, structured risk assessment instrument in acute care settings illustrates a recommendation that could facilitate the prevention of aggression. Similarly, some evidence supports using multimodal interventions consistent with the Six Core Strategies to reduce seclusion and restraint, even in populations with psychiatric diagnoses or symptomatology that may be difficult to treat.

Several questions may arise, however. Is currently available limited evidence sufficient for evaluating effectiveness? Should implementation decisions be delayed until more evidence becomes available? How should the substantial barriers to conducting RCTs in these populations, involving both the challenges of obtaining informed consent as well as limited funds supporting such research, be considered in weighing and acting on the available evidence? What is the role of quality measures, designed to create incentives for improving quality of care, if the evidence base for those measures is unclear?

Regarding the last question, we are unaware of any ongoing trials that will add to the current sparse body of evidence addressing the benefits of risk assessment protocols and multimodal interventions. Furthermore, we cannot comment on potential harms or costs associated with implementing risk assessment protocols. Therefore, determining how to apply interventions from other countries to settings in the United States—and determining the modifications that might be necessary to do so—are key next steps, given the absence of SOE findings from inpatient psychiatric settings in the United States.

Research Recommendations

The paucity of evidence means that most implications of our review pertain to future research rather than to clinical or policy judgments. Major evidence gaps exist in this increasingly worrisome clinical arena; they point to important next steps for research in preventing and de-escalating aggressive behavior in acute care settings. The SOE grades informing decision making in this area were minimal. A major void is the lack of well-designed, adequately powered, properly analyzed comparative trials that address questions of preventing and de-escalating aggressive behavior. The validity of findings from the three reasonably well-designed CRTs was constrained by analyses that did not properly control for the clustered nature of the data. We applaud the efforts to conduct comparative trials, but this evidence base does not convincingly show the efficacy of most of these strategies; that fact complicates the design of strong comparative studies and reflects a gap in efficacy data that may need to be addressed first.

Nonetheless, head-to-head trials that compare various interventions with each other rather than with usual care are needed to guide decision making. Most critical is identifying the "right" interventions to compare, which would allow the most efficient use of research time and funding for this topic. More evidence about the differential effectiveness of interventions would allow clinicians and administrators to balance evidence of effectiveness with implementation and resource costs.

Investigators who lead future trials must clearly describe their interventions. Only in this way can other research teams sensibly try to reproduce or replicate such studies and help confirm which components of the interventions are the most (or least) effective. Risk assessment strategies and multimodal interventions, which have some evidence for preventing aggressive behavior, must be described in more detail to allow comparisons with each other and to allow variations within these approaches to be compared as well.

Currently, clinicians and investigators do not know the accuracy of risk assessment tools. Because these tools are necessary to identify patients at high risk of aggressive behavior and, hence, to develop an effective plan to manage aggressive behavior, more work on documenting the measurement capabilities of these tools is needed. In the future, all trials must report on consistently defined and clinically meaningful outcomes, both short term and long term. Crucial short-term outcomes include reliable and valid measures of aggressive behavior and of seclusion and restraint actions. Using well-established, reliable, and valid assessments of aggression that can be harmonized across studies (and ideally countries) is crucial, as well, for future systematic reviews on these topics. In addition, research teams should increase adherence to the Consolidated Standards of Reporting Trials statement regarding the reporting of clinical trials, including CRTs (55).

Key long-term outcomes must involve more patientcentered outcomes, such as health-related quality of life. Patient perspectives of harms, including treatment preferences, in acute care settings are largely missing from the literature; this gap should be remedied. Measures of the use of health services are important, as are cost implications. Investigators should incorporate factors involving implementation of interventions, such as acceptability, feasibility, and sustainability, into their designs for intervention research in acute care settings.

Available acute care data are almost entirely from inpatient psychiatric settings and settings outside the United States. In the latter case, standard practices, patient populations, insurance coverage, costs, and various other variables may differ in the United States, perhaps considerably. Future well-designed studies of inpatient psychiatric settings must be conducted in U.S. settings. In addition, informative data must be collected from acute care medical and surgical units and from emergency department settings.

Finally, we had no informative data on modifiers of treatment effectiveness. Future studies, including comparative trials, must assess how variables may modify or mediate the effects of the interventions studied. These variables could include age and other sociodemographic or economic factors, specific primary diagnoses (and perhaps coexisting conditions), and explicit treatment components.

Our review had limitations. First, we bounded its scope to focus on data relevant to adults in acute care settings. This emphasis left out consideration of data from chronic care and psychiatric residential settings; it also omitted treatment of children and adolescents. In both these clinical areas, however, use of seclusion and restraint is common and potentially concerning (56). Second, to allow a meaningful synthesis of outcomes, we required that studies report at least one of our main outcomes-change in aggressive behavior or in seclusion and restraint use. This restriction may have reduced the number of eligible studies and the number of patient-centered outcomes we could examine, for example, by omitting outcomes such as improved quality of life and improved therapeutic relationship. However, synthesizing such data with the other collected outcomes would have been difficult and would likely have not affected our SOE findings.

Finally, we excluded reviews and primary studies that examined agitation as the primary outcome when evaluating the effectiveness of inpatient or acute care risk assessment protocols (12). This exclusion limited consideration of interventions to reduce agitation, which may also lead to decreased aggression. An evidence base for reducing agitation exists (39,57), and it may inform aggression management. The decision to focus on aggression and not agitation, although narrowing the scope of our review, also reduced the heterogeneity of the outcomes under examination. Each exclusion decision was made with the intention of focusing the review and controlling for important sources of heterogeneity. By better delineating situations in which agitation leads to aggression, future research can better guide selection of a specific intervention, for example, a psychotherapeutic approach versus medication.

CONCLUSIONS

Given the ethical imperative to treat all patients with dignity, the clinical mandate of finding evidence-based solutions to these mental health challenges, and the legal liability associated with failure to assess and manage violence risk across the treatment continuum, the need for evidence to guide clinical and policy decision making about de-escalating aggressive behavior is critical. This point is particularly true of acute care settings for at least two reasons: comprehensive clinical and violence risk information may not always be readily available in such institutions, and patient management must be balanced against staffing and treatment limitations unique to each setting.

The current evidence base provides clinicians, administrators, policy makers, and patients with no definitive guidance on how to best prevent and de-escalate aggressive behaviors in acute care settings. It suggests, however, that risk assessment is a reasonable strategy for decreasing aggression and reducing the use of seclusion and restraint and that a multimodal intervention approach based on the Six Core Strategies also reduces the use of seclusion and restraint. Evidence for the comparative effectiveness of strategies to de-escalate aggressive behavior is currently inadequate to give definitive advice about treatment selection. More research is needed to guide clinicians, administrators, and policy makers on how to best prevent and de-escalate aggressive behavior in acute care settings.

AUTHOR AND ARTICLE INFORMATION

Dr. Gaynes, Dr. Brown, Dr. Brownley, and Dr. Zarzar are with the Department of Psychiatry, University of North Carolina (UNC) at Chapel Hill School of Medicine, Chapel Hill. Dr. Brown is also with the Center for Excellence in Community Mental Health, and Mr. Coker-Schwimmer and Dr. Weber are with the Sheps Center for Health Services Research, UNC at Chapel Hill. Ms. Lux, Dr. Van Dorn, Dr. Edlund, Dr. Viswanathan, and Dr. Lohr are with Research Triangle Institute International, Research Triangle Park, Durham, North Carolina. Dr. Sheitman is with the Department of Psychiatry, UNC Health Care System, Chapel Hill. Send correspondence to Dr. Gaynes (e-mail: bradley_gaynes@med.unc.edu).

This project was funded under contract HHSA 290 2015 00011 I_ HHSA29032003T from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (DHHS). The authors are indebted to the following RTI-UNC EPC staff for their commitment and contributions to this project: Carol Woodell, B.S.P.H, Loraine Monroe, Sharon Barrell, M.A., Claire Baker, Charli Randolph, B.A., Catherine A. Grodensky, M.P.H., and Lynn Whitener, Dr.P.H., M.S.L.S. Additionally, the authors deeply appreciate the contributions of Atlas Research staff during the process of abstracting data from this project's eligible studies, including Reva Stidd, M.S., M.B.A., Jason Ormsby, Ph.D., M.B.A., and Abby Friedman. Statements in this report should not be construed as endorsement by the AHRQ or the DHHS.

Dr. Gaynes has served on the editorial board for Medscape Psychiatry and Mental Health, a continuing medical education organization. Dr. Brownley reports serving as a consultant to Sunovian Pharmaceuticals and the Shire Pharmaceuticals Research and Development Advisory Community, and she has served as a member of the Binge Eating Disorder Association's scientific advisory board. The other authors report no financial relationships with commercial interests.

Received July 6, 2016; revision received December 2, 2016; accepted January 5, 2017; published online April 15, 2017.

REFERENCES

- 1. Morrison EF: Violent psychiatric inpatients in a public hospital. Scholarly Inquiry for Nursing Practice 4:65–82, 1990
- National Association of State Mental Health Program Directors: Northern Virginia Mental Health Institute, Department of Nursing Services, Policies and Procedures. Seclusion or Restraint. Alexandria, VA, National Association of State Mental Health Program Directors, 2008. Available at http://www.nasmhpd.org/sites/default/ files/L_2_B_VA_NMHL_SRPolicies.pdf. Accessed Jan 19, 2015
- 3. Health Care Financing Administration: Medicare and Medicaid programs, conditions of participation: patients' rights. Interim final rule, 42 CFR 482. Federal Register 64:36069–36089, 1999
- 4. Comprehensive Accreditation Manual for Hospitals: The Official Handbook. Oakbrook Terrace, IL, Joint Commission Resources, 2000
- CMS Manual System. Baltimore, Centers for Medicare & Medicaid Services, 2008. https://www.cms.gov/Regulations-and-Guidance/ Guidance/Transmittals/downloads/R37SOMA.pdf
- Donat DC: An analysis of successful efforts to reduce the use of seclusion and restraint at a public psychiatric hospital. Psychiatric Services 54:1119–1123, 2003
- DeLacy L, Edner B, Hart C, et al: Learning From Each Other: Success Stories and Ideas for Reducing Restraint/Seclusion in Behavioral Health. Arlington, VA, American Psychiatric Association, American Psychiatric Nurses Association, and National Association of Psychiatric Health Systems, 2003. c.ymcdn.com/ sites/www.copaa.org/resource/collection/662B1866-952D-41FA-B7F3-D3CF68639918/Learning_from_each_other_-reducing_ restraint.pdf
- Janssen WA, van de Sande R, Noorthoorn EO, et al: Methodological issues in monitoring the use of coercive measures. International Journal of Law and Psychiatry 34:429–438, 2011
- 9. Cornaggia CM, Beghi M, Pavone F, et al: Aggression in psychiatry wards: a systematic review. Psychiatry Research 189:10–20, 2011
- Bowers L, Stewart D, Papadopoulos C, et al: Inpatient Violence and Aggression: A Literature Review. Report From the Conflict and Containment Reduction Research Programme. London, Kings College, Institute of Psychiatry, Section of Mental Health Nursing Health Service and Population Research, 2011. www.kcl.ac.uk/ioppn/ depts/hspr/research/ciemh/mhn/projects/litreview/LitRevAgg.pdf
- Huckshorn KA: Six Core Strategies for Reducing Seclusion and Restraint Use. Alexandria, VA, National Association of State Mental Health Program Directors, 2006. www.nasmhpd.org/sites/default/ files/Consolidated%20Six%20Core%20Strategies%20Document.pdf
- Zeller SL, Rhoades RW: Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clinical Therapeutics 32:403–425, 2010
- Champagne T, Stromberg N: Sensory approaches in inpatient psychiatric settings: innovative alternatives to seclusion and restraint. Journal of Psychosocial Nursing and Mental Health Services 42:34–44, 2004

- 14. Richmond JS, Berlin JS, Fishkind AB, et al: Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA de-escalation workgroup. Western Journal of Emergency Medicine 13:17–25, 2012
- Ashcraft L, Anthony W: Eliminating seclusion and restraint in recoveryoriented crisis services. Psychiatric Services 59:1198–1202, 2008
- Ashcraft L, Anthony WA: Crisis services in the "living room." Behavioral Healthcare 26:12–14, 2006
- Loucks J, Rutledge DN, Hatch B, et al: Rapid response team for behavioral emergencies. Journal of the American Psychiatric Nurses Association 16:93–100, 2010
- Smith GM, Ashbridge DM, Davis RH, et al: Correlation between reduction of seclusion and restraint and assaults by patients in Pennsylvania's state hospitals. Psychiatric Services 66:303–309, 2015
- 19. Gaynes BN, Brown C, Lux LJ, et al: Strategies to De-escalate Aggressive Behavior in Psychiatric Patients. Comparative Effectiveness Review no 180. AHRQ pub no 16-EHC032-EF. Rockville, MD, Agency for Healthcare Research and Quality, 2016. www. effectivehealthcare. ahrq.gov/reports/final.cfm
- 20. Balshem H, Stevens A, Ansari M, et al: Finding Grey Literature Evidence and Assessing for Outcome and Analysis Reporting Biases When Comparing Medical Interventions: AHRQ and the Effective Health Care Program. AHRQ pub no 13(14)-EHC096-EF. Rockville, MD, Agency for Healthcare Research and Quality, 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm
- 21. Viswanathan M, Ansari MT, Berkman ND, et al: Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. AHRQ pub no 12-EHC047-EF. Rockville, MD, Agency for Healthcare Research and Quality, 2012. www.effectivehealthcare. ahrq.gov/
- 22. Viswanathan M, Berkman ND: Development of the RTI item bank on risk of bias and precision of observational studies. Journal of Clinical Epidemiology 65:163–178, 2012
- 23. Gartlehner G, Gaynes BN, Amick HR, et al: Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder. Comparative Effectiveness Review no 161. Rockville, MD, Agency for Healthcare Research and Quality, 2015. effectivehealthcare.ahrq.gov/ehc/products/568/1923/major-depressivedisorder-protocol-141124.pdf
- 24. Berkman ND, Lohr KN, Ansari MT, et al: Grading the strength of a body of evidence when assessing health care interventions: an EPC update. Journal of Clinical Epidemiology 68:1312–1324, 2014
- Guyatt GH, Oxman AD, Kunz R, et al: GRADE guidelines 6: rating the quality of evidence—imprecision. Journal of Clinical Epidemiology 64:1283–1293, 2011
- 26. Isbister GK, Calver LA, Page CB, et al.: Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Annals of Emergency Medicine 56:392–401, 2010
- 27. Abderhalden C, Needham I, Dassen T, et al: Structured risk assessment and violence in acute psychiatric wards: randomised controlled trial. British Journal of Psychiatry 193:44–50, 2008
- 28. Dorevitch A, Katz N, Zemishlany Z, et al: Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry 156:142–144, 1999
- 29. Kontio R, Pitkänen A, Joffe G, et al: eLearning course may shorten the duration of mechanical restraint among psychiatric inpatients: a cluster-randomized trial. Nordic Journal of Psychiatry 68:443–449, 2014
- 30. Kontio R, Lahti M, Pitkänen A, et al: Impact of eLearning course on nurses' professional competence in seclusion and restraint practices: a randomized controlled study (ISRCTN32869544). Journal of Psychiatric and Mental Health Nursing 18:813–821, 2011
- Michaud CJ, Thomas WL, McAllen KJ: Early pharmacological treatment of delirium may reduce physical restraint use: a retrospective study. Annals of Pharmacotherapy 48:328–334, 2014

- 32. Putkonen A, Kuivalainen S, Louheranta O, et al: Cluster-randomized controlled trial of reducing seclusion and restraint in secured care of men with schizophrenia. Psychiatric Services 64:850–855, 2013
- Georgieva I, Mulder CL, Noorthoorn E: Reducing seclusion through involuntary medication: a randomized clinical trial. Psychiatry Research 205:48–53, 2013
- 34. Van de Sande R, Nijman HL, Noorthoorn EO, et al: Aggression and seclusion on acute psychiatric wards: effect of short-term risk assessment. British Journal of Psychiatry 199:473–478, 2011
- 35. Volavka J, Czobor P, Nolan K, et al: Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology 24:225–228, 2004
- 36. Volavka J, Czobor P, Sheitman B, et al: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 159:255–262, 2002
- Czobor P, Volavka J, Sheitman B, et al: Antipsychotic-induced weight gain and therapeutic response: a differential association. Journal of Clinical Psychopharmacology 22:244–251, 2002
- Bieniek SA, Ownby RL, Penalver A, et al: A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 18:57–62, 1998
- 39. Krakowski MI, Czobor P, Citrome L, et al: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63:622–629, 2006
- Krakowski MI, Czobor P, Nolan KA: Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Journal of Clinical Psychopharmacology 28:485–493, 2008
- Krakowski M, Czobor P, Citrome L: Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophrenia Research 110:95–102, 2009
- 42. Villari V, Rocca P, Fonzo V, et al: Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:405–413, 2008
- Carlson JM, Holm MB: Effectiveness of occupational therapy for reducing restraint use in a psychiatric setting. American Journal of Occupational Therapy 47:885–889, 1993
- 44. Nurenberg JR, Schleifer SJ, Shaffer TM, et al: Animal-assisted therapy with chronic psychiatric inpatients: equine-assisted psychotherapy and aggressive behavior. Psychiatric Services 66:80–86, 2015
- 45. Richards JR, Derlet RW, Duncan DR: Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine 16:567–573, 1998
- Smoot SL, Gonzales JL: Cost-effective communication skills training for state hospital employees. Psychiatric Services 46:819–822, 1995
- Wilhelm S, Schacht A, Wagner T: Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial. BMC Psychiatry 8:61, 2008
- Smith GM, Davis RH, Bixler EO, et al: Pennsylvania State Hospital system's seclusion and restraint reduction program. Psychiatric Services 56:1115–1122, 2005
- Sailas E, Fenton M: Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews 2: CD001163, 2000
- Bak J, Brandt-Christensen M, Sestoft DM, et al: Mechanical restraint—which interventions prevent episodes of mechanical restraint? A systematic review. Perspectives in Psychiatric Care 48: 83–94, 2012
- Muralidharan S, Fenton M: Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews 3:CD002084, 2006
- Hermanstyne KA, Mangurian C: Behavioral strategies to mitigate violent behavior among inpatients: a literature review. Psychiatric Services 66:557–558, 2015

- 53. Steinert T, Lepping P, Bernhardsgrütter R, et al: Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. Social Psychiatry and Psychiatric Epidemiology 45:889–897, 2010
- 54. Nelstrop L, Chandler-Oatts J, Bingley W, et al: A systematic review of the safety and effectiveness of restraint and seclusion as interventions for the short-term management of violence in adult psychiatric inpatient settings and emergency departments. Worldviews on Evidence-Based Nursing 3:8–18, 2006
- 55. Moher D, Hopewell S, Schulz KF, et al: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery 10:28–55, 2012
- Improper Restraint or Seclusion Use Places People at Risk: Report to Congressional Requesters. Washington, DC, United States General Accounting Office, 1999
- 57. Bosanac P, Hollander Y, Castle D: The comparative efficacy of intramuscular antipsychotics for the management of acute agitation. Australasian Psychiatry 21:554–562, 2013

First-Person Accounts Invited for Column

Patients, family members, and mental health professionals are invited to submit first-person accounts of experiences with mental illness and treatment for the Personal Accounts column in *Psychiatric Services*. Maximum length is 1,600 words.

Material to be considered for publication should be sent to the column editor, Jeffrey L. Geller, M.D., M.P.H., at the Department of Psychiatry, University of Massachusetts Medical School (e-mail: jeffrey.geller@umassmed.edu). Authors may publish under a pseudonym if they wish.